Alexandria Venture

Alexandria Venture

Pulse 2.0

Editas Medicine Stock (EDIT): Why The Price Jumped Today

Pulse 2.0

Seres Therapeutics (MCRB) Stock: Why The Price Increased Today

MedCity News

Seres Therapeutics microbiome drug flunks Phase 2 test in ulcerative colitis

$50,000,000 Venture capital (Series B)

Seattle startup TwinStrand raises $50M to expand tech that identifies rare genetic mutants


Relay Therapeutics Snaps up ZebiAI with $85 Million Upfront Payment

$100,000,000 Venture capital (Series D)
VentureBeat , FinSMEs

Synthego raises $100 million for AI-driven gene editing

MedCity News

Relay Therapeutics prices IPO at $400M

Bloomberg Technology

SoftBank-Backed Relay Therapeutics Seeks $265 Million in IPO

MedCity News

Protein motion-focused Relay Therapeutics files for $200M IPO

$16,000,000 Venture capital (Series A)
FinSMEs , Pulse 2.0

TwinStrand Biosciences Raises $16M in Series A Funding

$40,000,000 Venture capital (Series D)

Aura Biosciences Completes $40M Series D Financing

MedCity News

Editas Medicine CEO steps down as company moves into product development stage

$400,000,000 Venture capital (Series C)
FinSMEs , PE HUB , VentureBeat

Relay Therapeutics Secures $400M in Series C Financing

$110,000,000 Venture capital (Series C)
FinSMEs , StartupWorld , PE HUB

Synthego Raises $110M in Series C financing

Funding Science
TechCrunch , VentureBeat

Synthego raises $110 million to make gene editing technologies more accessible

Robotics Science
$60,000,000 Venture capital (Series C)

Benson Hill Biosystems Raises $60M Financing


Otsuka completes Visterra acquisition for about $430 mln

$4,000,000 Venture capital (Series A)
FinSMEs , MedCity News , PE HUB , +1

ApoGen Biotechnologies Raises $4m in Series A Funding

Funding Health Science

Otsuka to buy VC-backed Visterra for about $430 mln


Synthego's new products give scientists access to edited genetic material